Hartley M G, Hudson M J, Swarbrick E T, Grace R H, Gent A E, Hellier M D
PHLS Centre for Applied Microbiology & Research, Salisbury, UK.
Aliment Pharmacol Ther. 1996 Apr;10(2):157-63. doi: 10.1046/j.1365-2036.1996.723115000.x.
To study the influence of sulphasalazine treatment on the mucosa-associated bacterial flora of rectal biopsy tissue specimens in patients with ulcerative colitis.
Twenty-four patients had newly diagnosed active ulcerative colitis; 20 patients had acute relapse of ulcerative colitis (10 not taking maintenance sulphasalazine); (40 patients had quiescent ulcerative colitis; 21 not taking maintenance sulphasalazine). The influence of 3 weeks of sulphasalazine treatment on the mucosa-associated flora was studied in the patients presenting with active disease.
Comparison of patients according to sulphasalazine usage revealed few differences in the mucosal flora. In patients with quiescent ulcerative colitis, Escherichia coli was found at lower counts in patients taking maintenance sulphasalazine; however, this effect was not evident in patients with active disease. Inconsistent changes in other facultatives were seen between the two active disease groups, particularly for a miscellaneous group of unidentified Gram-positive rods. Three patients, all receiving sulphasalazine, were colonized with Clostridium difficile, but this did not appear to influence their disease.
Sulphasalazine treatment in ulcerative colitis causes only minor disturbance to the populations of bacteria colonizing the colorectal mucosa.
研究柳氮磺胺吡啶治疗对溃疡性结肠炎患者直肠活检组织标本中黏膜相关细菌菌群的影响。
24例为新诊断的活动性溃疡性结肠炎患者；20例为溃疡性结肠炎急性复发患者（其中10例未服用维持剂量的柳氮磺胺吡啶）；40例为静止期溃疡性结肠炎患者（其中21例未服用维持剂量的柳氮磺胺吡啶）。对活动性疾病患者研究了柳氮磺胺吡啶治疗3周对黏膜相关菌群的影响。
根据柳氮磺胺吡啶使用情况对患者进行比较，发现黏膜菌群差异不大。在静止期溃疡性结肠炎患者中，服用维持剂量柳氮磺胺吡啶的患者大肠埃希菌数量较低；然而，在活动性疾病患者中这种效应并不明显。两个活动性疾病组之间其他兼性菌的变化不一致，特别是对于一组未鉴定的革兰氏阳性杆菌。3例均接受柳氮磺胺吡啶治疗的患者感染了艰难梭菌，但这似乎并未影响他们的病情。
溃疡性结肠炎患者接受柳氮磺胺吡啶治疗对在结直肠黏膜定植的细菌种群仅造成轻微干扰。
